ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The National Comprehensive Cancer Network (NCCN) and the European Leukemia Net (ELN) both have recommended BCR::ABL1 KD mutation testing in CML patients who do not achieve an optimal response to TKI therapy16,31,32.